HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis
Leukemia · 2025
DOI: 10.1038/s41375-024-02496-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia, 2025. Verfasst von Shivani Handa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: HMGA2 Protein, Primary Myelofibrosis, Repressor Proteins, Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Although multiple genetic events are thought to play a role in promoting progression of the myeloproliferative neoplasms (MPN), the individual events that are associated with the development of more aggressive disease phenotypes remain poorly defined. Here, we report that novel genomic deletions at chromosome 12q14.3, as detected by a high-resolution array comparative genomic hybridization plus single nucleotide polymorphisms platform, occur in 11% of MPN patients with myelofibrosis (MF) and MPN-accelerated/blast phase (AP/BP) but was not detected in patients with polycythemia vera or essential thrombocythemia. These 12q14.3 deletions resulted in the loss of most of the non-coding region of exon 5 and MIRLET7 binding sites in the 3'UTR of the high mobility group AT hook 2 (HMGA2), which negatively regulate HMGA2 expression. These acquired 12q14.3 deletions were predominately detected in MF patients with CALR and ASXL1 co-mutations and led to a greater degree of HMGA2 transcript overexpression, independent of the presence of an ASXL1 mutation. Patients with 12q structural abnormalities involving HMGA2 exhibited a more aggressive clinical course, with a higher frequency of MPN-AP/BP evolution. These findings indicate that HMGA2 overexpression associated with genomic deletion of its 3'UTR region is a newly recognized genetic event that contributes to MPN progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
- Department of Pathology and Molecular Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ronald.hoffman@mssm.edu.
- Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. vesna.najfeld@mssm.edu.
- Department of Pathology and Molecular Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. vesna.najfeld@mssm.edu.
ORCID-Profile: Christoph Schaniel, Joseph Tripodi, Md Babu Mia, Douglas Tremblay, Ronald Hoffman, Vesna Najfeld
Förderung
- NCI NIH HHS
Zitieren
APA
Handa, S., Schaniel, C., Tripodi, J., Ahire, D., Mia, M. B., Klingborg, S., Tremblay, D., Marcellino, B. K., Hoffman, R., & Najfeld, V. (2025). HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis. Leukemia. https://doi.org/10.1038/s41375-024-02496-0
Vancouver
Handa S, Schaniel C, Tripodi J, Ahire D, Mia MB, Klingborg S, et al. HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis. Leukemia. 2025. doi:10.1038/s41375-024-02496-0
BibTeX
@article{Handa2025,
author = {Handa, Shivani and Schaniel, Christoph and Tripodi, Joseph and Ahire, Daiva and Mia, Md Babu and Klingborg, Sophie and Tremblay, Douglas and Marcellino, Bridget K and Hoffman, Ronald and Najfeld, Vesna},
title = {HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis},
journal = {Leukemia},
year = {2025},
doi = {10.1038/s41375-024-02496-0}
}
EUVIMED